Slough, United Kingdom

Thomas Allen Ceska

USPTO Granted Patents = 7 

 

Average Co-Inventor Count = 4.1

ph-index = 2

Forward Citations = 9(Granted Patents)


Location History:

  • Berkshire, GB (2017)
  • Slough, GB (2014 - 2024)

Company Filing History:


Years Active: 2014-2024

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: Innovations of Thomas Allen Ceska

Introduction

Thomas Allen Ceska is a notable inventor based in Slough, GB. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for therapeutic use. With a total of 7 patents to his name, Ceska's work has the potential to impact the treatment of various disorders.

Latest Patents

One of his latest patents focuses on improved anti-IgE antibodies and antigen binding agents. This invention targets IgE, which is crucial for treating disorders caused by IgE, such as allergic responses and certain autoimmune disorders. The patent details the development of novel mutants of omalizumab (Xolair®) that may exhibit enhanced affinity for IgE and improved interactions with the Cε2 domain of IgE. Another significant patent involves antibodies specific to FcRn, which includes formulations and therapeutic applications of these antibodies.

Career Highlights

Throughout his career, Thomas Ceska has worked with prominent companies in the pharmaceutical industry, including UCB Biopharma and UCB Pharma. His experience in these organizations has contributed to his expertise in developing innovative therapeutic solutions.

Collaborations

Ceska has collaborated with notable professionals in his field, including Alistair James Henry and Paul Alan Atherfold. These collaborations have likely enriched his research and development efforts.

Conclusion

Thomas Allen Ceska's contributions to the field of biotechnology through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in the treatment of IgE-mediated disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…